Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review (Q37027541)

17 August 2017

1 reference

title

Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review (English)

1 reference

brain natriuretic peptide

17 August 2017

0 references

0 references

chronic heart failure

1 reference

Wolfgang Herrmann

1

1 reference

17 August 2017

Markus Herrmann

series ordinal

2

1 reference

17 August 2017

Jacob Joseph

series ordinal

3

1 reference

17 August 2017

Suresh C Tyagi

series ordinal

4

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Clinical Chemistry and Laboratory Medicine

17 August 2017

published in

1 reference

17 August 2017

volume

45

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1633-1644

1 reference

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine is an independent risk factor for myocardial infarction, in particular fatal myocardial infarction in middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine lowering and cardiovascular events after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine lowering with folic acid and B vitamins in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Efficacy of folic acid supplementation in stroke prevention: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Improvement in stroke mortality in Canada and the United States, 1990 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Acute negative inotropic effects of homocysteine are mediated via the endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Generation of nitrotyrosine precedes activation of metalloproteinase in myocardium of hyperhomocysteinemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Incidence and epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The heart failure epidemic: exactly how big is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Management of heart failure in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Risk factors for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The Natural History of Congestive Heart Failure: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Biochemical detection of left-ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The importance of hyperhomocysteinemia as a risk factor for diseases: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Facts and recommendations about total homocysteine determinations: an expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine and left ventricular hypertrophy in children with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The Hordaland Homocysteine Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Guidelines for the diagnosis and treatment of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Relationship of plasma homocysteine with the severity of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance--pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Hyperhomocysteinemia in patients with heart failure referred for cardiac transplantation: Preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Cellular uptake of vitamin B12 in patients with chronic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Folate, vitamin B12, and sulfur amino acid levels in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Renal insufficiency as an independent predictor of mortality among women with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The clinical challenge of cardiorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Vitamin C inhibits endothelial cell apoptosis in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Experimental Hyperhomocysteinemia Reduces Bone Quality in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Matrix metalloproteinase inhibition and the prevention of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Proteinases and myocardial extracellular matrix turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Homocysteine induces metalloproteinase and shedding of beta-1 integrin in microvessel endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Mechanisms of homocysteine-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Arrhythmia and neuronal/endothelial myocyte uncoupling in hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

Elevated Homocysteine Is Associated With Reduced Regional Left Ventricular Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.360

21 January 2018

Identifiers

DOI

10.1515/CCLM.2007.360

1 reference

17 August 2017

1 reference